Wednesday 23 July 2014

Amgen growth in Brazil picks up, eyes doubling portfolio by 2020

By Alberto Alerigi and Brad Haynes SAO PAULO (Reuters) - Amgen Inc, the world's biggest biotechnology company, has had a surge in sales in Brazil this year and it plans to double its drug portfolio in the country by the end of the decade, the company's top local executive says. Eduardo Santos, head of Amgen Brasil, said in a recent interview that revenue rose 54 percent from a year earlier in the first half of 2014, more than double the company's average annual growth in Brazil since it arrived three years ago. Citing competitive concerns, he declined to say how much Brazil contributed to Amgen's $18.7 billion revenue in 2013, but he said the unit has reached financial self-sufficiency. The release of three patented Amgen drugs in Brazil this year boosted sales and helped expand the drugmaker's local business beyond its unpatented medicines, which will face rising competition in coming years. via Health News Headlines - Yahoo News Read More Here..

No comments:

Post a Comment